The natural course of nonculprit coronary artery lesions; analysis by serial quantitative coronary angiography by Kang, Jeehoon et al.
RESEARCH ARTICLE Open Access
The natural course of nonculprit coronary
artery lesions; analysis by serial quantitative
coronary angiography
Jeehoon Kang1, Kyung Woo Park1* , Michael S. Lee2, Chengbin Zheng1, Jung-Kyu Han1, Han-Mo Yang1,
Hyun-Jae Kang1, Bon-Kwon Koo1 and Hyo-Soo Kim1
Abstract
Background: Nonculprit lesions are the major cause of future cardiovascular events. However, the natural course of
nonculprit lesions and angiographic predictors of plaque progression are not well-studied. The purpose of our study
was to observe the natural course of nonculprit lesions, and to identify predictors of unanticipated future events and
angiographic progression in nonculprit lesions.
Methods: We analyzed 640 nonculprit lesions with a length of ≥2 mm and luminal narrowing ≥30% from 320 patients
who had two serial angiographic follow-ups; 9 to 13 months post-PCI and 24 months post-PCI. The study endpoints were
nonculprit-ischemia driven revascularization (IDR) and the rate of diameter stenosis (DS) progression. Those with
progression of DS > 12%/year were defined as ‘rapid progressors’.
Results: During the median follow-up period of 737 days, 20 lesions in 20 patients (6.3%) required
nonculprit-IDR. Independent predictors of nonculprit-IDR were diabetes (hazard ratio [HR] 2.93, 95%
confidence interval [CI] 1.072–8.007, p = 0.036) and lesion type B2/C (HR 4.017, 95% CI 1.614–9.997, p = 0.003).
The presence of one or both of the two major risk factors was associated with significant DS progression (3.0
± 6.8% vs. 3.5 ± 6.1% vs. 6.8 ± 9.9% for lesions with 0, 1 and both risk factors, p < 0.001). Among the 640
lesions, 38 lesions (5.9%) in 33 patients were rapid progressors, while risk factors of rapid progressors included
lesion type B2/C as a lesion-related risk factor (HR 1.998, 95% CI 1.006–3.791, p = 0.048) and diabetes mellitus
as a patient-related risk factor (HR 3.725, 95% CI 1.937–7.538, p < 0.001). Lesions with both risk factors (type
B2/C lesions in diabetic patients) were at the highest risk of rapid progression (odds ratio 3.250, 95% CI 1.
451–7.282), compared to type A/B1 lesions in non-diabetic patients.
Conclusion: Nonculprit-IDR was not uncommon during the 2-year follow up period in our population. The
major risk factors of nonculprit lesion progression were diabetes and lesion type B2/C.
Trial registration: Retrospectively registered and approved by the institutional review board of Seoul National
University Hospital (No.: 1801–138-918) on February 2nd, 2018.
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Background
Nonculprit lesions account for a significant portion of fu-
ture adverse cardiac events [1]. A previous study reported
that nearly half of the major adverse cardiovascular events
were associated with nonculprit lesions during a 3-year
follow-up [2]. In the clinic, we can occasionally meet coron-
ary artery disease patients with initially insignificant noncul-
prit lesions, which rapidly progress to cause ischemia
despite standard medical treatment. These patients show a
higher incidence of heart failure, recurrent acute coronary
syndrome, leading to deterioration of the patients’ quality
of life [3]. Recent studies have described a few mechanisms
to explain the rapid progression in coronary stenosis, in-
cluding coronary vasospasm [4], a complex stenosis morph-
ology [5], and the systemic inflammatory status [6].
However, these mechanisms are putative, and studies on
the progression of nonculprit lesions are limited. Therefore,
efforts to detect the predictors of nonculprit lesion progres-
sion could prevent unanticipated future events related to
these lesions.
Current studies of plaque progression focus on the rup-
ture of vulnerable plaques, which present as myocardial in-
farction or cardiac death [7–9]. These studies mostly used
intravascular ultrasound (IVUS) or optical coherence tom-
ography (OCT) to evaluate plaque characteristics. However,
IVUS and OCT are invasive techniques which are not rou-
tinely used to characterize insignificant lesions. In fact, clin-
ical characteristics and coronary angiography, which is the
most commonly used method to initially assess coronary le-
sions are the only information available [10].
In this study, we analyzed insignificant, non-treated le-
sions, performed a longitudinal analysis using serial
quantitative coronary angiography (QCA). We observed
the natural course of nonculprit lesions, and identified
the predictors of unanticipated future events and angio-
graphic progression in nonculprit lesions.
Methods
Study design and population
Coronary artery disease patients, who receive PCI in our
institute, were enrolled in a stent registry at the time of
the index procedure (i.e. Everolimus, Zotarolimus, or
Biolimus eluting stent registry). According to the proto-
col of the individual registries, a follow up CAG was rec-
ommended (which is not mandatory) at 9 to 13 months
post-PCI. Of those that agreed to and received the first
follow up angiogram, a second routine follow up angio-
gram was recommended at 24 months. During the study
period (July 2008 to March 2013), 3044 patients were
enrolled in various stent registries, and 1486 patients
(48.8%) received 9 to 13 month follow up CAG. Among
these patients, 320 patients (21.9%) had a second routine
follow up CAG at 24 months post-PCI. Patients with le-
sions of a lesion length of ≥2 mm and luminal narrowing
≥30% at baseline angiography were included in the ana-
lysis. As a sensitivity analysis to check the possibility of
selection bias, the baseline demographics were compared
with that of the entire 3044 patients that received PCI
during the study period (Additional file 1: Table S2).
The study was approved by the ethics committee and
institutional review board and was conducted according
to the principles of the Declaration of Helsinki. All pa-
tients provided written, informed consent for participa-
tion in the registry.
Quantitative coronary angiography
Coronary angiograms were recorded at baseline and at two
serial follow-up periods. Analysis was done at the angio-
graphic core laboratory by 3 specialized quantitative coron-
ary angiography technicians at the Seoul National
University Hospital Cardiovascular Clinical Research Cen-
ter Angiographic Core Laboratory. Standard qualitative and
quantitative analyses and definitions were used for angio-
graphic analysis [11]. The ACC/AHA lesion classification
system, comprising 11 angiographic variables with all le-
sions categorized into types (A, B1, B2 and C) were used to
characterize lesions [12]. Measured variables included the
reference vessel diameter, the minimal luminal diameter
(MLD), and the diameter stenosis (DS). Delta DS was de-
fined as the last DS minus the initial DS (DS at 1st
follow-up when an adverse event occurred at the 1st
follow-up, DS at 2nd follow-up when an adverse event oc-
curred at the 2nd follow-up or in event-free cases.). Regard-
ing reliability analysis, the intra-observer intraclass
correlation (ICC) was 0.941 (95% CI 0.929–0.951) and the
inter-observer ICC was 0.986 (95% CI 0.973–0.992).
Study endpoints and definitions
The study endpoints were any event of nonculprit-ischemia
driven revascularization (IDR) and the rate of DS progres-
sion during the follow-up period. Revascularization was de-
fined as ischemia-driven if there was stenosis of at least
50% of the diameter with evidence of ischemia, as docu-
mented by a positive functional study, ischemic changes on
an electrocardiogram, or ischemic symptoms. In the ab-
sence of documented ischemia, DS of at least 70% was
required.
The definition of ‘rapid progressors’ was derived using
the following method. A previous study reported that the
rate of non-culprit lesion related clinical event was ap-
proximately 10% during 3 years of follow-up [2]. There-
fore, we analyzed the cutoff point for DS progression in
the upper 10% of the population using a histogram ana-
lysis. From this analysis ‘rapid progressors’ were defined as
patients with at least one lesion that had DS progression
more than 1% per month (or 12% per year). This is the
rate of DS progression that would turn an average lesion
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in our study, into a significant one during the 24 month
follow-up period.
Statistical analysis
Continuous variables were presented as mean ± standard
deviation and were compared using Student’s t-test or the
Mann-Whitney U test. Categorical variables were presented
as proportions, and chi-square test or Fisher’s exact test
was applied to compare differences between groups, as ap-
propriate. A comparison of baseline and follow-up values
of the QCA results were analyzed by paired t-tests. To de-
termine the independent predictors of nonculprit-IDR, a
Cox proportional hazard model was used. Factors included
into the multivariate model were lesion type, diameter of
reference vessel, lesion location of the coronary artery as
lesion-related factors, and age, gender, body mass index,
diabetes, hypertension, chronic kidney disease, dyslipid-
emia, previous MI, smoking, and clinical diagnosis of ST
segment elevation myocardial infarction as clinical factors.
A multiple logistic generalized estimating equations (GEE)
modeling using the autoregressive structure, was performed
to analyze the longitudinal changes on lesion characteristics
and clinical parameters as independent variables versus the
progression of nonculprit lesions as the dependent variable.
Variable included in the GEE model were identical to that
included in the Cox proportional hazard model. Two-sided
P values less than 0.05 were considered statistically signifi-
cant for all tests. All statistical analyses were performed
using SPSS version 20.0 (IBM Co., Chicago, IL, USA).
Results
Between July, 2008, and March, 2013, a total of 320 pa-
tients with 640 lesions were enrolled in this study. Base-
line demographic and clinical characteristics, initial
laboratory findings and discharge medications of the
study population are summarized in Additional file 1:
Table S1. To show absence of selection bias of our study
population, baseline demographics were compared with
the total population whom received PCI during the
study period (3044 patients, during July 2008 to March
2013; Additional file 1: Table S2) [13]. The mean
follow-up duration from baseline to the first and second
angiography was 326 ± 92 days and 759 ± 161 days re-
spectively (Fig. 1). Laboratory findings at the follow-up
periods are shown in Additional file 1: Table S3.
Baseline lesion analysis and ischemia driven
revascularization
Among the 640 baseline nonculprit lesions, 220 (34.4%)
were located in the left anterior descending coronary ar-
tery, 181 (28.3%) in the left circumflex coronary artery,
237 (37.0%) in the right coronary artery, and 2 (0.3%) in
the left main coronary artery. Also, 164 (25.6%) were
proximal lesions, 152 (23.8%) were mid lesions, 171
(26.7%) were distal lesions and 153 (23.9%) were branches
of epicardial coronary arteries. Baseline QCA revealed a
lesion length of 11.4 ± 7.7 mm with a DS of 45.1 ± 10.5,
29.8% had a DS > 50, and 2.5% had a DS > 70%. There was
no difference in lesion character in DM and non-DM pa-
tients (Additional file 1: Table S4).
The total follow-up duration was 640.3 patient-years.
During the median follow-up period of 737 days, 20 le-
sions in 20 patients (6.3%) required nonculprit-IDR.
Clinical and lesion characteristics between those with
and without IDR are shown in Table 1. Patients who re-
ceived nonculprit-IDR were more likely to have diabetes
mellitus or chronic renal failure, and discharge medica-
tion pattern were similar between the two groups. Le-
sions that received IDR had a smaller MLD, larger DS,
and were more likely to be B2/C lesions.
Fig. 1 Study flow of the study
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Table 1 Clinical and Lesion characteristic of lesions receiving ischemia-driven revascularization
Clinical Factors IDR (+) (20 patients) IDR (−) (300 patients) P value
Age (years old) 62.5 ± 9.9 65.9 ± 10.3 0.152
BMI (kg/m2) 24.3 ± 3.2 24.8 ± 2.9 0.449
Gender (male), n (%) 16 (80.0) 223 (74.1) 0.557
Previous PCI, n (%) 2 (10.0) 35 (11.6) 0.825
Previous CABG, n (%) 1 (5.0) 3 (1.0) 0.119
Previous MI, n (%) 2 (10.0) 22 (7.3) 0.661
Previous CHF, n (%) 3 (1.0) 0 (0.0) 0.816
Diabetes mellitus, n (%) 12 (60.0) 96 (31.9) 0.010
Hypertension, n (%) 13 (65.0) 213 (70.8) 0.584
CRF, n (%) 2 (10.0) 7 (2.3) 0.044
Dyslipidemia, n (%) 9 (45.0) 190 (63.1) 0.106
Current smoking, n (%) 13 (65.0) 164 (55.2) 0.394
FHx of CAD, n (%) 1 (5.0) 35 (11.7) 0.610
Clinical diagnosisa, n (%) 60.0 / 25.0 / 5.0 / 10.0 64.7 / 18.7 / 10.7 / 6.0 0.616
Diagnosis of ACS, n (%) 8 (40.0) 106 (35.5) 0.688
LV ejection fraction (%) 61.2 ± 7.9 59.7 ± 8.8 0.482
WBC (109/L) 7200 ± 2200 6800 ± 2300 0.550
Hemoglobin (g/dL) 13.8 ± 1.8 13.5 ± 1.8 0.485
Creatinine(mg/dL) 1.49 ± 1.43 1.08 ± 0.65 0.215
- eGFR (ml/min/1.73m2) 63.6 ± 28.4 72.9 ± 20.4 0.056
HbA1c (%) 7.2 ± 1.8 7.0 ± 1.0 0.693
Total cholesterol (mg/dl) 161 ± 31 157 ± 40 0.667
Triglyceride (mg/dl) 135 ± 56 136 ± 85 0.935
HDL-cholesterol (mg/dl) 44 ± 9 43 ± 11 0.585
LDL-cholesterol (mg/dl) 98 ± 31 97 ± 36 0.870
CRP (mg/dl) 0.41 ± 1.13 0.42 ± 1.23 0.981
Discharge Medications
- Aspirin 20 (100%) 299 (99.7%) 0.796
- Clopidogrel 20 (100%) 299 (99.7%) 0.796
- Beta blocker 17 (85.0%) 213 (71.0%) 0.178
- ARB / ACE inhibitors 13 (65.0%) 140 (46.7%) 0.112
- Calcium channel blockers 5 (25.0%) 63 (21.0%) 0.672
- Statins 20 (100%) 296 (98.7%) 0.603
- High intensity statin 3 (15.0%) 77 (25.9%) 0.778
Lesion factors IDR (+) (20 lesions) IDR (−) (620 lesions) P
Lesion length (mm) 16.14 ± 14.79 11.25 ± 7.35 0.157
Lesion locationb, (%) 30.0/40.0/30.0/0.0 34.5/27.9/37.3/0.2 0.692
Lesion proximityc, (%) 20.0 / 15.0 / 30.0 / 30.0 26.5 / 24.8 / 27.5 / 24.5 0.703
Lesion typed, (%) 30.0 / 10.0 / 30.0 / 30.0 34.8 / 31.3 / 21.9 / 11.9 0.035
B2/C lesion type 12 (60.0%) 210 (33.9%) 0.016
Minimal lumen diameter (mm) 1.31 ± 0.49 1.59 ± 0.49 0.013
Reference diameter (mm) 2.86 ± 0.52 2.84 ± 0.57 0.868
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The independent baseline patient-level and
lesion-level correlates of nonculprit-IDR were diabetes
(hazard ratio [HR] 3.698, 95% confidence interval [CI]
1.377–9.933, p = 0.009) and lesion type B2/C (HR
3.510, 95% CI 1.376–8.955, p = 0.009), respectively.
The rate of nonculprit-IDR for lesions increased along
with the number of risk factors, showing a rate of
1.8, 1.8 and 11.9%, for lesions that included 0, 1, or
both risk factors, respectively. Kaplan Meier curve of
nonculprit-IDR events, according to the number of
risk factors is shown in Fig. 2. The combination of
these two risk factors increased the risk of IDR by at
least 6-fold compared with any single risk factor.
QCA analysis of the natural progression of atherosclerotic
plaques
During the total follow-up period, the mean MLD de-
creased (1.58 ± 0.49 mm vs. 1.50 ± 0.48 mm vs. 1.46 ±
0.48 mm, p < 0.001, at baseline, 1st follow-up and 2nd
follow-up, respectively) whereas the mean angiographic
DS increased (45.1 ± 10.6 vs. 47.1 ± 11.2 vs. 48.2 ± 11.2,
p < 0.001, at baseline, 1st follow-up and 2nd follow-up,
respectively), suggesting continuous progression of
angiographic stenosis (mean delta DS: 3.73 ± 7.09%) A
dot plot of the baseline DS and delta DS of each lesion
is shown in Fig. 3. Also, the velocity of DS progression
was 2.46 ± 6.70%/year until the 1st follow-up, 1.49 ±
4.17%/year from the 1st follow-up to the 2nd follow-up
period, and 2.19 ± 5.47%/year during the total follow-up
period. A histogram of the velocity of all lesions is in
Additional file 1: Figure S1. Lesions with nonculprit-IDR
events had a larger delta DS (22.1 ± 15.4% vs. 3.1 ± 5.8%,
p < 0.001) and faster rate of DS progression (21.12 ±
17.17%/year vs. 1.58 ± 3.14%/year, p < 0.001) compared
to those without events.
Predictors of progression
To investigate the predictors of DS progression, we
used a GEE model for repeated measures. After cor-
recting for the size and location of the coronary ar-
tery, male sex, low BMI (< 25 kg/m2), diabetes
mellitus, and lesion type B2/C were significant risk
factors for a higher DS. Among these factors, diabetes
mellitus and lesion type B2/C lesions showed inter-
action with time during the follow-up period. In other
words, patients with diabetes mellitus and type B2/C
lesions showed faster progression of angiographic
stenosis compared with those without these factors
(Additional file 1: Table S5). The mean DS and mean
delta DS according to the presence of 0, 1 or 2 risk
Table 1 Clinical and Lesion characteristic of lesions receiving ischemia-driven revascularization (Continued)
Clinical Factors IDR (+) (20 patients) IDR (−) (300 patients) P value
Initial DS 54.3 ± 13.1% 44.8 ± 10.3% < 0.001
Last DS 75.8 ± 14.8 47.9 ± 10.7% < 0.001
Delta DS 22.1 ± 15.4% 3.1 ± 5.8% < 0.001
BMI body mass index, PCI percutaneous coronary intervention, MI Myocardial infarction, CABG coronary artery bypass graft surgery, CHF Congestive heart failure,
FHx family history, CAD coronary artery disease, LV left ventricle, WBC white blood cell, HDL high density lipoprotein cholesterol, LDL low density lipoprotein
cholesterol, CRP C-reactive protein, ARB Angiotensin II receptor blockers, ACE Angiotensin-converting-enzyme, DS diameter stenosis
aClinical diagnosis: Stable angina / Unstable angina / non ST-segment elevation myocardial infarction / ST-segment elevation myocardial infarction
bLesion location: Left anterior descending artery / Left circumflex artery / Right coronary artery / Left main coronary artery
cLesion proximity: Proximal lesion / Mid lesion / Distal lesion / Side branch
dLesion type: Lesion type A / Lesion typeB1 / Lesion type B2 / Lesion type C
Fig. 2 Survival curve of nonculprit-IDR. Nonculprit-IDR was significantly more frequent in lesions with both risk factors (diabetes and lesion
type B2/C)
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factors are shown in Table 2. Compared with the angio-
graphic stenosis progression of lesions with 0 or 1 risk fac-
tor, those with 2 risk factors had a significantly faster
progression (delta DS of lesions with both risk factors:
2.3-fold larger compared to those with no risk factors and
1.9-fold larger compared to those with 1 risk factor). This
was also consistent with comparison of the velocity of DS
progression, where lesions with both risk factors showed a
2.8-fold larger velocity of DS progression.
Among the 640 lesions, 38 lesions (5.9%) in 33 pa-
tients were defined as rapid progressors, defined as a
progression of DS more than 1% year month or more
than 12% per year. The GEE model for repeated mea-
sures revealed lesion type B2/C as a lesion-related risk
factor for rapid progressors with a OR 2.139 (95% CI
1.066–4.294, p = 0.032) and diabetes mellitus as a
patient-related risk factor (OR 2.782, 95% CI 1.349–
5.737, p = 0.006). Lesions with both risk factors of dia-
betes and lesion type B2/C were at the highest risk of
rapid progression (13/273 [4.8%] vs. 12/283 [4.0%] vs.
13/84 [15.5%], p < 0.001 for lesions with 0, 1, and 2 risk
factors, respectively), with an odds ratio of 3.250 (95%
CI, 1.451–7.282), compared to type A/B1 lesions in
non-diabetic patients (Fig. 4).
Discussion
In this study, the natural course of initially insignificant
coronary artery lesions 6.3% of patients underwent
nonculprit-IDR. Diabetes and lesion type B2/C were the
major independent risk factors of nonculprit-IDR. The
DS increased by 3.7 ± 7.1% (rate of 2.19 ± 5.47% per ob-
served year) during the total follow-up period. The pres-
ence of both major risk factors resulted in a 2.8-fold
faster DS progression compared to one or no risk factor.
Rapid progression was found in 5.9% of lesions. Diabetes
and lesion type B2/C were again the major predictors of
rapid progression, and lesions with both risk factors
Fig. 3 Dot plot of Initial DS and Delta DS
Table 2 Initial and final Diameter Stenosis according to number of risk factors
Group 1a Group 2a Group 3a P value
No risk factors 1 risk factor 2 risk factors
Initial DS 42.9 ± 9.6% 46.0 ± 11.0% 48.8 ± 10.5% Overall < 0.001
Group 1 vs. Group 2 0.001
Group 2 vs. Group 3 0.075
Group 1 vs. Group 3 < 0.001
Final DS 46.0 ± 9.7% 49.5 ± 12.0% 55.5 ± 14.6% Overall < 0.001
Group 1 vs. Group 2 0.001
Group 2 vs. Group 3 < 0.001
Group 1 vs. Group 3 < 0.001
Delta DS 3.0 ± 6.8% 3.5 ± 6.1% 6.8 ± 9.9% Overall < 0.001
Group 1 vs. Group 2 0.703
Group 2 vs. Group 3 0.001
Group 1 vs. Group 3 < 0.001
Velocity of DS progression 0.150 ± 0.402%/month 0.154 ± 0.298%/month 0.422 ± 0.956%/month Overall < 0.001
Group 1 vs. Group 2 0.995
Group 2 vs. Group 3 < 0.001
Group 1 vs. Group 3 < 0.001
aGroup 1 implies those with diabetes mellitus (−) and B2C lesions (−). Group 2 implies diabetes mellitus (+), B2C lesions (−) or diabetes mellitus (−), B2C lesions (+)
and Group 3 implies diabetes mellitus (+) & B2C lesions (+)
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showed a 3.25-fold higher risk of rapid progression,
compared to those with no risk factors.
Natural history of coronary plaques
The pathophysiology of coronary plaque formation has
been studied for decades. Inflammation was identified as
the primary driving force for activation and proliferation
of smooth muscle cells, a processes mediated by growth
factors. [14] Lesion progression can be induced by lipid
accumulation, endothelial damage, or plaque erosion
which involves many factors such as clinical risk factors of
the individual, mechanical forces, etc. [15] Progression to
a vulnerable plaque (known as thin cap fibroatheroma)
[16], or injury such as deep plaque fissures or ulcerations,
can cause acute coronary syndrome. [17]
Imaging techniques such as IVUS and OCT have been
used to evaluate lesions and provide valuable informa-
tion on plaque and lumen character. For example, the
PROSPECT (Providing Regional Observations to Study
Predictors of Events in the Coronary Tree) trial demon-
strated that vulnerable plaques which are most likely to
cause sudden unexpected adverse cardiac events can be
pre-identified through IVUS imaging techniques. [2] In
this study, the 3-year cumulative rate of major adverse
cardiovascular events was 20.4%, among which, 11.6%
were related to non-culprit lesions. Predictors for
non-culprit lesions related events included insulin
dependent diabetes and previous PCI as patient related
factors, and a plaque burden of 70% or greater or a min-
imal luminal area of 4.0 mm2 or less or thin-cap
fibroatheromas lesions as lesion related factors. In
addition, the PROSPECT II trial is ongoing trial which
will assess the ability of intracoronary near infrared spec-
troscopy (NIRS) to identify vulnerable plaques which
subsequently lead to coronary events.
However, even these sophisticated imaging tools have
shortcomings. For example invasive imaging tools can-
not evaluate distal lesions, increases the time and ex-
pense of PCI and may cause coronary dissection or
plaque erosion through physical contact. Also, evaluating
the entire coronary vasculature with these tools is a sig-
nificant clinical burden to both the clinician and patient.
[18] Therefore, we still need more feasible angiographic
standards for lesion evaluation.
In our study, we analyzed non-culprit lesions with ser-
ial coronary angiography and QCA, which permitted
more detailed analysis. Compared to the PROSPECT
trial, we could analyze the angiographic progression in
every non-culprit lesion, including those which were not
related to clinical events. We calculated the average
angiographic progression rate in non-culprit lesions, the
predictors of rapid progression, and also the predictors
of clinical events. Regarding the fact that IVUS cannot
be performed in every patient that we meet in the clinic,
our results may give clinicians a more practical guideline
for future events related with non-culprit lesions.
Predictors of revascularization in nonculprit coronary
plaques
Our population, in general, was receiving optimal med-
ical therapy, with dual antiplatelet agents and lipid low-
ering agents. Previous studies have shown that statins
Fig. 4 Rate of ‘Rapid Progressors’ by risk factor. Significantly more ‘Rapid progressors’ in lesions with both risk factors (diabetes and lesion
type B2/C)
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could induce atheroma regression in coronary artery dis-
ease patients. [19, 20] Regarding lipid lowering agents,
93.8% were on statin, and the LDL level was very
well-controlled, being 97 ± 35 mg/dL at the initial state
and 67 ± 22 mg/dL and 65 ± 20 mg/dL at the 1st and
2nd follow-up respectively, suggesting that the study
population, on average, were receiving appropriate statin
therapy.
During the 2-year follow-up period, nonculprit-related
events occurred in 6.3% of the patients, which were all
revascularization events with no events of MI or
nonculprit-related cardiac death. This was a similar rate
to a previous study, where revascularization occurred in
10.5% during a 3-year follow-up. [2] Among lesion fac-
tors showing difference between those who and who did
not experience nonculprit-IDR (i.e. smaller initial MLD,
larger DS and had a higher proportion of lesion type B2/
C), we were able to identify one lesion characteristic that
was a significant predictor of subsequent events: lesion
type B2/C. Diabetes was the only significant clinical fac-
tor to predict nonculprit IDR.
Lesion progression and rapid progressors
Nonculprit lesions showed progression in DS at a vel-
ocity of approximately 2.2%/year. Factors associated with
a faster progression over the follow-up period, were
identical to those risk factors of nonculprit-IDR; diabetes
and lesion type B2/C. It is well-known that local factors,
such as tortuosity and irregular contours of the lesion
(incorporated in the lesion type definition [12]) and sys-
temic factors, such as diabetes both are related to lesion
progression. [21, 22] From our result, lesions with risk
factors had a 1.5-fold faster velocity of DS progression,
compared to those without risk factors.
Among the total lesions, 5.9% were rapid progressors,
with a progression of DS more than 1% year month or
more than 12% per year. From the histogram of velocity
of DS progression, there was a distinct group of lesions
with faster progression. Predictors of rapid progression
were identical to that of nonculprit-IDR (i.e. diabetes
and lesion type B2/C); however there was a distinct pat-
tern in the effect size of each risk factor. For predictors
of nonculprit-IDR, lesion type B2/C had a larger effect
size compared to diabetes, whereas predictors of rapid
progressors, the effect size of diabetes was larger than
that of lesion type B2/C. This can be partially explained
by the character of the outcomes; nonculprit-IDR and
rapid progressors. As nonculprit-IDR is outcome that
embodies the discretion of the operator, high risk
morphology of the coronary lesion, such as lesion type
B2/C, could have influenced the procedure. On the other
hand, rapid progressors was an angiographic finding
which is free from any interference by the eye of the op-
erator. Therefore, a more ‘ugly’ morphology of the
nonculprit lesion, could have had more influence on
nonculprit-IDR, compared to rapid progressors.
Limitation
Although we performed a serial angiographic analysis of
nonculprit lesion, our study has several important limi-
tations. One inherent limitation is due to angiography it-
self. Even to the most experienced eye, angiography is a
lumenogram yielding little insight into plaque compos-
ition or lesion pathology. It is well-known that plaques
that show different composition have different out-
comes, and that plaque composition does not always
correlate with DS. Information regarding plaque charac-
ter is something that is unobtainable from angiography.
Also, other than morphology, fluid mechanics such as
coronary wall shear stress is known to be associated with
plaque progression, which was not analyzed. Second,
due to the retrospective nature of our study, there could
have been a selection bias in patient selection. We com-
pared the baseline clinical characteristics with the total
parent population whom received PCI during the study
period, and we found minimal difference between the
two populations. However, we cannot complete deny
possibilities of other selection bias within our study
population.
Conclusion
Nonculprit-IDR was not an uncommon event during the
2-year follow up period in our population. Diabetes and
lesion type B2/C are the major risk factors for nonculprit
lesion IDR. Also, regarding angiographic progression, le-
sions with both risk factors showed a significantly rapid
progression in DS compared to those with one or no
risk factor.
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